Stockscreener 앱 받기
0.8755
5.49%
-0.0509
시간 외 거래:
.89
0.0145
+1.66%
Inozyme Pharma Inc 주식(INZY)의 최신 뉴스
Rare Disease Innovator Inozyme Pharma Reveals Latest Progress at Elite Healthcare Conference - Stock Titan
Inozyme Pharma to Participate in the 24th Annual Needham Virtual Healthcare Conference - Bluefield Daily Telegraph
Inozyme Pharma, Inc. (NASDAQ:INZY) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Inozyme Pharma stock hits 52-week low at $0.98 amid sharp decline By Investing.com - Investing.com South Africa
Inozyme Pharma stock hits 52-week low at $0.98 amid sharp decline - Investing.com Australia
FY2027 EPS Estimates for Inozyme Pharma Raised by Analyst - Defense World
Raymond James Issues Pessimistic Forecast for Inozyme Pharma (NASDAQ:INZY) Stock Price - Defense World
Q1 Earnings Estimate for Inozyme Pharma Issued By Wedbush - Defense World
Q1 EPS Estimates for Inozyme Pharma Reduced by HC Wainwright - Defense World
Piper Sandler Has Lowered Expectations for Inozyme Pharma (NASDAQ:INZY) Stock Price - Defense World
Inozyme Pharma (NASDAQ:INZY) Price Target Lowered to $15.00 at Needham & Company LLC - Defense World
Inozyme Pharma’s (INZY) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Piper Sandler cuts Inozyme Pharma stock target to $23 By Investing.com - Investing.com Australia
Inozyme Pharma stock hits 52-week low at $1.03 amid sharp decline - Investing.com
Piper Sandler cuts Inozyme Pharma stock target to $23 - Investing.com
H.C. Wainwright maintains Buy on Inozyme stock with $16 target By Investing.com - Investing.com Australia
H.C. Wainwright maintains Buy on Inozyme stock with $16 target - Investing.com
Wedbush Reaffirms Outperform Rating for Inozyme Pharma (NASDAQ:INZY) - The AM Reporter
Inozyme Pharma Focuses on ENPP1 Deficiency Program - TipRanks
Inozyme Pharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Wedbush Cuts Inozyme Pharma Price Target to $7 From $12, Maintains Outperform Rating - Marketscreener.com
Inozyme reports prioritization of ENPP1 Deficiency program, workforce reduction - TipRanks
Inozyme Pharma Reports 2024 Financial Results and Strategic Prioritization of ENPP1 Deficiency Program - Nasdaq
Inozyme Pharma, Inc. SEC 10-K Report - TradingView
Form 10-K Inozyme Pharma, Inc. For: Dec 31 - StreetInsider
Inozyme Pharma Reports Full Year 2024 Financial Results and Announces Strategic Prioritization ... - Bluefield Daily Telegraph
Inozyme Pharma Reports Full Year 2024 Financial Results and Announces Strategic Prioritization of ENPP1 Deficiency Pivotal Program and Recent Business Highlights - The Manila Times
Inozyme Pharma Reports Full Year 2024 Financial Results and - GlobeNewswire
Inozyme Pharma (INZY) Projected to Post Earnings on Tuesday - Defense World
Inozyme Pharma Inc expected to post a loss of 41 cents a shareEarnings Preview - TradingView
Inozyme Pharma, Inc. (NASDAQ:INZY) Receives $18.33 Consensus PT from Analysts - Armenian Reporter
INZY stock touches 52-week low at $1.14 amid market challenges - Investing.com
Inozyme Pharma, Inc. (NASDAQ:INZY) Given Average Rating of "Buy" by Brokerages - MarketBeat
Inozyme Pharma, Inc. (NASDAQ:INZY) Given Average Rating of “Buy” by Brokerages - Defense World
Inozyme Pharma stock hits 52-week low at $1.23 amid challenges - Investing.com Canada
Inozyme Pharma to Present at the TD Cowen 45th Annual Health Care Conference - GlobeNewswire
Can Inozyme's Rare Disease Pipeline Transform Bone Health Treatment? CEO Presents Key Data - StockTitan
Inozyme Pharma to Present Recently Announced Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency at CHOP Cardiology 2025 - The Manila Times
Inozyme Pharma to Present Recently Announced Interim Data - GlobeNewswire
Can This Rare Disease Treatment Transform Young Lives? New ENPP1 Therapy Data Emerges - StockTitan
Inozyme Pharma stock hits 52-week low at $1.32 amid market challenges - MSN
abrdn plc Makes New $472,000 Investment in Inozyme Pharma, Inc. (NASDAQ:INZY) - Defense World
Inozyme Pharma Inc (NASDAQ: INZY) Stock Falling -48.58% Over A Month – Any Room For Its Value To Rise? - Marketing Sentinel
Inozyme Pharma, Inc. (NASDAQ:INZY) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
INZY Stock: A Comprehensive Analysis and Forecast - The InvestChronicle
Was anything positive for Inozyme Pharma Inc (INZY) stock last session? - US Post News
1.23%
1.63%
자본화:
|
볼륨(24시간):